Business
Novartis Cholesterol Drug Failure Triggers Biopharma Selloff
Shares of Novartis and peers plummet after its pelacarsen trial showed no reduction in cardiovascular events despite lowering Lp(a) levels.
Tag: Lp(a)
Yovao News · The World, In Focus.
From Local to Global, Never Miss a Beat